Abstract:Inflammatory bowel disease (IBD) is a chronic and recurrent intestinal inflammatory disease, mainly including Crohn's disease (CD) and ulcerative colitis (UC). In recent years, the incidence and prevalence of IBD have been on the rise worldwide and have become a significant concern of health and a huge economic burden on patients. The occurrence and development of IBD involve a variety of pathogenic factors. The changes in short-chain fatty acids (SCFAs) are considered to be an important pathogenic mechanism of this disease. SCFAs are important metabolites in the intestinal microbial environment, which are closely involved in regulating immune, anti-tumor, and anti-inflammatory activities. Changes in metabolite levels can reflect the homeostasis of the intestinal microflora. Recent studies have shown that SCFAs provide energy for host cells and intestinal microflora, shape the intestinal environment, and regulate the immune system, thereby regulating intestinal physiology. SCFAs can effectively reduce the incidence of enteritis, cardiovascular disease, colon cancer, obesity, and diabetes, and also play an important role in maintaining the balance of energy metabolism (mainly glucose metabolism) and improving insulin tolerance. In recent years, many studies have shown that numerous decoctions and natural compounds of traditional Chinese medicine have shown promising therapeutic activities in multiple animal models of colitis and thus attracted increasing attention from scientists in the study of IBD treatment. Some of these traditional Chinese medicines or compounds can effectively alleviate colonic inflammation and clinical symptoms by regulating the generation of SCFAs. This study reviews the effects of various traditional Chinese medicines or bioactive substances on the production of SCFAs and their potential impacts on the severity of colonic inflammation. On this basis, we discussed the mechanism of SCFAs in regulating IBD-associated inflammation, as well as the related regulatory factors and signaling pathways. In addition, we provide our understanding of the limitations of current research and the prospects for future studies on the development of new IBD therapies by targeting SCFAs. This review may widen our understanding of the effect of traditional medicine from the view of SCFAs and their role in alleviating IBD animal models, thus contributing to the studies of IBD researchers.

Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation

Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases

Regulatory role of short-chain fatty acids in inflammatory bowel disease

Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases

Role of short chain fatty acids in gut health and possible therapeutic approaches in inflammatory bowel diseases

Short‐chain fatty acids: bridges between diet, gut microbiota, and health

Short Chain Fatty Acids: Essential Weapons of Traditional Medicine in Treating Inflammatory Bowel Disease

Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease

The Role of Short Chain Fatty Acids in Inflammation and Body Health

Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota

Participation of Short-Chain Fatty Acids and Their Receptors in Gut Inflammation and Colon Cancer

Role of short-chain fatty acids in host physiology

The role of short-chain fatty acids in inflammatory skin diseases

Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease

Regulation of inflammation by short chain fatty acids

Are Short Chain Fatty Acids in Gut Microbiota Defensive Players for Inflammation and Atherosclerosis?

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

[The role of short-chain fatty acids in inflammatory bowel diseases and colorectal cancer]

Gut microbiota derived short-chain fatty acids in physiology and pathology: An update

The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy

Short-Chain Fatty Acids Modulate Healthy Gut Microbiota Composition and Functional Potential